Cerebrolysin
Compound snapshot
Class
Porcine brain-derived peptide mixture
FDA approved
No in the United States; marketed in some countries
Clinical development
Phase 3
Last reviewed
September 2026
Research areas
Cognition / Mood / Neuroprotection
Regulatory status
Prescription medicine in some countries — not FDA-approved
Internet attention
Moderate
Registry query
Cerebrolysin
Not one defined peptide, but a porcine-brain-derived mixture of low-molecular-weight peptide fragments and free amino acids. It is marketed as a prescription medicine in parts of Eastern Europe and Asia for neurological conditions.
Reality check — what we actually know
Supported by human evidence
- This compound has completed human trials in at least one approved indication — see the regulatory section for what was actually approved.
Animal research only
- Some randomised stroke trials report modest improvements in early neurological scores
- Systematic reviews find uncertain or inconsistent effects on independence, disability and mortality after stroke
- Dementia and traumatic-brain-injury studies have produced mixed findings
Mechanistically plausible
- The mixture is proposed to produce neurotrophic-factor-like effects, influence neuroplasticity, and reduce excitotoxic, oxidative and inflammatory injury. Because its active components are not fully defined, it has no single confirmed molecular target.
Common internet claims
- Online discussion frequently presents Cerebrolysin as a proven treatment rather than a research compound.
Not established
- Human efficacy for the outcomes commonly claimed
- Optimal route, quantity and duration in humans
- Long-term human safety
Evidence distribution
Each band is a live PubMed search for Cerebrolysin, filtered to that kind of study. Top is the strongest evidence; the base is reasoning, not proof. A band with no records means that kind of study has not been published for this compound yet.
Mechanism and reported findings
The mixture is proposed to produce neurotrophic-factor-like effects, influence neuroplasticity, and reduce excitotoxic, oxidative and inflammatory injury. Because its active components are not fully defined, it has no single confirmed molecular target.
- Some randomised stroke trials report modest improvements in early neurological scores
- Systematic reviews find uncertain or inconsistent effects on independence, disability and mortality after stroke
- Dementia and traumatic-brain-injury studies have produced mixed findings
- Its clinical trial base is larger than that of most research-market peptides, but trial quality and regional bias remain concerns
Strength of the evidence: Moderate in volume but inconsistent in quality and outcome. Cochrane review evidence does not establish a clear overall benefit in acute ischaemic stroke, and results should not be generalized across neurological diseases.
Safety and known cautions
Not FDA-approved and not interchangeable with a single synthetic peptide. It is an animal-derived injectable mixture requiring medical supervision where licensed. Allergy, infection-control, product consistency and uncertain clinical benefit must be considered.
Evidence at a glance
No single score, on purpose. The line beside each bar shows how much reported outcomes vary between studies.
Development stage
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3Current
- Regulatory review
- Approved